Antonio Beltran, MD
Pulmonary Disease · Long Beach, CANPI 1104023514
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,170 of the $20,059 with a category attached, or 80.6%. Merck accounts for 96.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $14,010 and has fallen 98.4% since, to $230 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $202.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$19K
- Boehringer Ingelheim$284
- Chiesi USA, Inc.$251
- Vapotherm Inc$139
- GSK$47
- Shionogi Inc$34
- plus $48 from 3 others
What the payments were for
- Speaking & faculty fees$16,17081%
- Travel & lodging$1,4087%
- Food & beverage$2,45312%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 86 | $19,256 |
| Boehringer Ingelheim | 4 | $284 |
| Chiesi USA, Inc. | 1 | $251 |
| Vapotherm Inc | 1 | $139 |
| GSK | 3 | $47 |
| Shionogi Inc | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Monaghan Medical Corporation | 1 | $15 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,059 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 181 | $141,675 |
| Breo ElliptaFluticasone/Vilanterol | 161 | $69,794 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 77 | $38,226 |
| Spiriva RespimatTiotropium Bromide | 40 | $23,786 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 47 | $22,678 |
| Incruse ElliptaUmeclidinium Bromide | 36 | $11,715 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 355 | $10,433 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $8,590 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $5,858 |
| EliquisApixaban | 14 | $5,404 |
| Atrovent HfaIpratropium Bromide | 12 | $5,339 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $4,853 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $3,849 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $3,679 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $3,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $47 | $261,411455 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $284 | $55,055106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Long Beach
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.